OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT)
Tal Sella, Yue Zheng, Nabihah Tayob, et al.
npj Breast Cancer (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 5
Tal Sella, Yue Zheng, Nabihah Tayob, et al.
npj Breast Cancer (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 5
Showing 5 citing articles:
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial
Sara M. Tolaney, Paolo Tarantino, Noah Graham, et al.
The Lancet Oncology (2023) Vol. 24, Iss. 3, pp. 273-285
Closed Access | Times Cited: 99
Sara M. Tolaney, Paolo Tarantino, Noah Graham, et al.
The Lancet Oncology (2023) Vol. 24, Iss. 3, pp. 273-285
Closed Access | Times Cited: 99
Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT
Paolo Tarantino, Nabihah Tayob, Guillermo Villacampa, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 31, pp. 3652-3665
Closed Access | Times Cited: 13
Paolo Tarantino, Nabihah Tayob, Guillermo Villacampa, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 31, pp. 3652-3665
Closed Access | Times Cited: 13
Health-related quality of life in Her2-positive early breast cancer woman using trastuzumab: A systematic review and meta-analysis
Sudewi Mukaromah Khoirunnisa, Fithria Dyah Ayu Suryanegara, Didik Setiawan, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 4
Sudewi Mukaromah Khoirunnisa, Fithria Dyah Ayu Suryanegara, Didik Setiawan, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 4
Appraisal of Systemic Treatment Strategies in Early HER2-Positive Breast Cancer—A Literature Review
Danilo Giffoni de Mello Morais Mata, Rania Chehade, Malek B. Hannouf, et al.
Cancers (2023) Vol. 15, Iss. 17, pp. 4336-4336
Open Access | Times Cited: 3
Danilo Giffoni de Mello Morais Mata, Rania Chehade, Malek B. Hannouf, et al.
Cancers (2023) Vol. 15, Iss. 17, pp. 4336-4336
Open Access | Times Cited: 3
Adjuvant Trastuzumab Emtansine Versus Paclitaxel and Trastuzumab in Stage I HER2-Positive Breast Cancer: The ATEMPT Trial
Monica N. Khattak, Anna Chichura, Julie E. Lang
Annals of Surgical Oncology (2023) Vol. 31, Iss. 3, pp. 1423-1427
Open Access | Times Cited: 1
Monica N. Khattak, Anna Chichura, Julie E. Lang
Annals of Surgical Oncology (2023) Vol. 31, Iss. 3, pp. 1423-1427
Open Access | Times Cited: 1
